If you have been reading about modified GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Charcot–Marie–Tooth (CMT) disease is an inherited neurological disorder primarily caused by genetic mutations that disrupt critical proteins within peripheral nerves. These mutations predominantly affect proteins essential for the structure and function of the myelin sheath, including peripheral myelin protein 22 (PMP22), myelin protein zero (P0/MPZ), connexin32 (Cx32/GJB1), and periaxin (PRX), leading to demyelination. Additionally, mutations in proteins involved in axonal integrity, such as neurofilament light chain (NF-L), dynamin 2 (DNM2), ganglioside-induced differentiation-associated protein 1 (GDAP1), and mitofusin 2 (MFN2), can cause axonal forms of CMT. Due to the close interaction between Schwann cells (which produce myelin) and axons, mutations affecting Schwann cells often result in secondary axonal degeneration, further complicating disease progression. Ultimately, the pathogenesis of CMT involves the disruption of essential cellular processes, including protein synthesis, sorting, intracellular transport, protein degradation, and mitochondrial function, highlighting the complex molecular mechanisms underlying this disorder.
President Donald Trump has stated the goals of the war were to destroy Iran's ballistic missiles, eliminate their navy, prevent them from acquiring nuclear weapons, and to stop Iranian proxies from holding power. Trump asserted that Iran's ballistic missile program could endanger US allies "throughout the world", including Europe and American mainland. Pete Hegseth said that Iran would be capable of nuclear blackmail with their ballistic missiles if the US did not attack it. However, a Defense Intelligence Agency assessment determined that Iran would not be capable of building intercontinental ballistic missiles until 2035. Secretary of State Marco Rubio warned that Iran posed an "imminent threat" to US bases in the event of Israeli strikes on Iran, thereby portraying the war as a preemptive one. Mike Johnson, the Speaker of the United States House of Representatives and Rubio said that Israel was going to attack Iran, after which Iran's retaliations against US bases would have brought them into war anyway. Senator Mark Warner of the Senate Intelligence Committee who was briefed by Rubio before the war began said that there was no evidence that Iran was going to launch a pre-emptive strike against the US, and that the war was ultimately decided upon by Israel. Trump rejected these claims, stating that "I might have forced their hands.
In the blockchain, bitcoins are linked to specific strings called addresses. Most often, an address encodes a hash of a single public key. Creating such an address involves generating a random private key and then computing the corresponding address. This process is almost instant, but the reverse (finding the private key for a given address) is nearly impossible. Publishing such a bitcoin address does not risk its private key, and it is extremely unlikely to accidentally generate a used key with funds. To use bitcoins, owners need their private key to digitally sign transactions, which are verified by the network using the public key, keeping the private key secret. An address may encode the hash of a bitcoin script that specifies more complex requirements to spend the funds. One common example is "multisig", in which multiple distinct private keys must mutually sign any transaction that attempts to spend the funds. Bitcoin transactions use a Forth-like scripting language, involving one or more inputs and outputs. When sending bitcoins, a user specifies the recipients' addresses and the amount for each output. This allows sending bitcoins to several recipients in a single transaction. To prevent double-spending, each input must refer to a previous unspent output in the blockchain. Using multiple inputs is similar to using multiple coins in a cash transaction. As in a cash transaction, the sum of inputs can exceed the intended sum of payments. In such a case, an additional output can return the change back to the payer.
=== In genetic disorders === Many genetic disorders involve hereditary defects in receptor genes. Often, it is hard to determine whether the receptor is nonfunctional or the hormone is produced at decreased level; this gives rise to the "pseudo-hypo-" group of endocrine disorders, where there appears to be a decreased hormonal level while in fact it is the receptor that is not responding sufficiently to the hormone.
Sources: en.wikipedia.org
=== Role in Cardiovascular Events === The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP)-phosphodiesterase (PDE) pathway has become a target in developing treatments for heart failure. A deficit in cGMP levels has been associated with adverse cardiovascular outcomes, promoting factors like myocardial fibrosis, vasoconstriction, and inflammation, all of which accelerate heart failure progression. Some soluble guanylate cyclase (sGC) stimulators, have yielded promising outcomes in reducing cardiovascular events. Their effectiveness is thought to result from increased sensitivity of sGC to endogenous NO. Elevated plasma cGMP levels, regulated predominantly by natriuretic peptides (NP) rather than nitric oxide (NO), were found to correlate with a higher risk of heart failure, atherosclerotic cardiovascular disease, and coronary heart disease.
Evidence indicating that Early to Middle Pleistocene hominins from the northern Indian Subcontinent lived in a mosaic environment dominated by savannas is presented by Kaur et al. (2026). Tu et al. (2026) determine the three crania of Homo erectus from the Yunxian site (Hubei, China) to be approximately 1.77 million years old, representing the oldest securely dated hominin fossils from eastern Asia reported to date. Gousset et al. (2026) study the phylogenetic relationships of Homo luzonensis, and interpret the studied hominin as most likely originating from an Asian population of Homo erectus, resulting in evolutionary reversals in an insular context and likely caused by living in tropical environment. A study on the technological characteristics of the stone tools from the Rizal Archaeological Site (Philippines) is published by Guibert et al. (2026). Li et al. (2026) report a new Lower Paleolithic site with stone tools and animal remains (the Daanmiao site) in the Bailong River valley (Gansu, China) providing evidence of hominin occupation of western Qinling Mountain Ranges approximately 900,000 years ago, and evidence of more favorable habitat for early hominins in the studied area than in other parts of North China during the Mid-Pleistocene Transition. Shao et al. (2026) determine two hominin crania from the Hulu Cave (China) to likely fall within a similar chronological range and date them to Marine Isotope Stage 16. Fu et al.
== Further reading == Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part I. Pathophysiology". Journal of the American Academy of Dermatology. 62 (3): 361–70, quiz 371–2. doi:10.1016/j.jaad.2009.10.042. PMID 20159304. Khan, Misbah H.; Victor, Frank; Rao, Babar; Sadick, Neil S. (2010). "Treatment of cellulite. Part II. Advances and controversies". Journal of the American Academy of Dermatology. 62 (3): 373–84, quiz 385–6. doi:10.1016/j.jaad.2009.10.041. PMID 20159305.
== Availability in different countries == In Canada, the UK, and the United States, SAM is sold as a dietary supplement under the marketing name SAM-e (also spelled SAME or SAMe). It was introduced in the US in 1999, after the Dietary Supplement Health and Education Act was passed in 1994. It was introduced as a prescription drug in Italy in 1979, in Spain in 1985, and in Germany in 1989. As of 2012, it was sold as a prescription drug in Russia, India, China, Italy, Germany, Vietnam, and Mexico.
=== Distribution === From 1977 to 1981, SOLAR was distributed by RCA Records, which had also distributed the Soul Train Records label during its two-year run. Griffey formed a second label, Constellation Records (no relation to the Chicago-based indie label founded by Ewart Abner) in 1981, which focused on more contemporary and top forty-geared acts to Griffey's more traditionally "urban" establishment (including Jon Gibson and Klymaxx). Upon its formation, Constellation was distributed through Elektra/Asylum Records, making it only natural for the main SOLAR label to jump ship to Elektra for distribution when it left RCA. In the meantime, the Constellation label moved to MCA Records for distribution in 1984. Shortly thereafter, Griffey decided to abandon contemporary music to focus all of his attention on running SOLAR, and retaining its sonic theme. Subsequently, MCA bought the Constellation imprint and absorbed its artists, including Klymaxx, which had been its biggest act. SOLAR's relationship with Elektra lasted until 1986. After the Elektra distribution deal expired, SOLAR briefly took up distribution with Capitol Records until 1989, at which time it signed a new distribution deal with Epic Records, which oversaw what would ultimately become its twilight years. In the early 1990s, the label released its last recordings- 1991's Now by Richie Havens and Times 3's eponymous debut album, the soundtrack to the 1992 film Deep Cover, 3rd Avenue's 1992 debut album Let's Talk About Love, and 1993 The Deele album An Invitation To Love.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.